Cepheid’s Shares Rise 12.3 Percent; Sequenom Drops 10.2 Percent | GenomeWeb
Shares of Cepheid rose 12.3 percent for the five-day trading week ended Tuesday. Last week, the firm said that it had received European clearance and began marketing its Xpert MRSA/SA-Blood Cultures and Xpert MRSA/SA-Skin and Soft Tissue Infection SSTI molecular diagnostic tests.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.